A new screening strategy for ovarian cancer appears to be highly specific for detecting the disease before it becomes lethal.
The strategy is described in a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society. If verified in an ongoing clinical trial, it could potentially help save the lives of thousands of women each year in the United States alone.
There currently are no established screening strategies for ovarian cancer. The disease often causes no specific symptoms and is difficult to detect in the early stages when it is most responsive to treatment. Therefore, ovarian cancer is highly lethal because most women have advanced disease when they are diagnosed.
Karen Lu, MD, of The University of Texas MD Anderson Cancer Center in Houston, led a team that tested the potential of a two-stage ovarian cancer screening strategy that incorporates changes in a blood protein called CA125, which is a known tumor marker. In their 11-year study, 4051 post- menopausal women initially underwent an annual CA125 blood test. Based on a calculation called the “Risk of Ovarian Cancer Algorithm,” women were divided into three groups: those who should receive another CA125 test one year later (low risk), those who should receive a repeat CA125 in three months (intermediate risk), and those who should receive a transvaginal ultrasound and be referred to a gynecologic oncologist (high risk).
An average of 5.8 percent of women were found to be of intermediate risk each year, meaning that they should receive a CA125 test in three months. The average annual referral rate to transvaginal ultrasound and review by a gynecologic oncologist was 0.9 percent. Ten women underwent surgery based on their ultrasound exams, with four having invasive ovarian cancers, two having ovarian tumors of low malignant potential, one having endometrial cancer, and three having benign ovarian tumors. This equates to a positive predictive value of 40 percent for detecting invasive ovarian cancer. The specificity of the testing strategy was 99.9 percent, meaning that only 0.1 percent of patients without cancer would be falsely identified as having the disease. Importantly, all of the ovarian cancers were early stage.
The Latest on: Ovarian cancer
- Cancer Risk Genes: Everything You Need to Know About BRCA1 and BRCA2 on June 18, 2019 at 4:11 pm
To put that in perspective, women in the general population have about a 12 percent chance of developing breast cancer at some point in their lives. (3) The risk of developing ovarian cancer is also ... […]
- Cancer Risk Genes: Everything You Need to Know About BARD1 on June 18, 2019 at 4:10 pm
If a woman has a change, or mutation, in the BARD1 gene, she may be more likely to develop breast cancer and possibly ovarian cancer. It’s not known if men with a BARD1 alteration have an increased ... […]
- Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers on June 18, 2019 at 3:04 pm
Height and body mass index (BMI) are associated with higher ovarian cancer risk in the general population, but whether such associations exist among BRCA1/2 mutation carriers is unknown. All prices ... […]
- LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer on June 18, 2019 at 4:28 am
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved LYNPARZA as monotherapy for the maintenance treatment of ... […]
- Merck's LYNPARZA OK'd in EU for ovarian cancer on June 18, 2019 at 3:59 am
The European Commission has approved LYNPARZA (olaparib), jointly developed by AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) as monotherapy for the maintenance treatment of adult patients with ... […]
- Ovarian Cancer Market Size, Top Vendors, Growth rate, Latest Trends and Forecasts to 2026 on June 18, 2019 at 2:31 am
Jun 18, 2019 (marketresearchupdates.com via COMTEX) -- StraitsResearch.com offers the latest published report on Ovarian Cancer market which is the most important research for who looks for complete ... […]
- AstraZeneca's Lynparza Gets EU Nod as First-Line Ovarian Cancer Maintenance Treatment on June 17, 2019 at 11:47 pm
(Reuters) - British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European ... […]
- Oasmia Pharmaceutical AB: Swedish Company Targeting Ovarian Cancer, But Doesn't Impress on June 17, 2019 at 4:50 pm
OASM’s drug is already approved in multiple geographies. However, we agree with a dissenting CHMP opinion that doesn’t find the drug well-differentiated from SoC. US FDA may look at things ... […]
- Hundreds come together to spread awareness about ovarian cancer on June 15, 2019 at 5:42 pm
More than 500 people gathered at Baker Park in Frederick Saturday, all sporting teal t-shirts, to spread awareness about ovarian cancer. The 5K walk around the park brought together cancer survivors ... […]
- Telenovela star Edith González dies at 54 of ovarian cancer on June 13, 2019 at 7:59 pm
MEXICO CITY – Telenovela star Edith González has died at age 54 from ovarian cancer. The National Association of Actors of Mexico confirmed the death of the “Corazón salvaje,” “Palabra de mujer” and ... […]
via Google News and Bing News